全文获取类型
收费全文 | 3013篇 |
免费 | 184篇 |
国内免费 | 19篇 |
专业分类
耳鼻咽喉 | 21篇 |
儿科学 | 60篇 |
妇产科学 | 26篇 |
基础医学 | 377篇 |
口腔科学 | 47篇 |
临床医学 | 201篇 |
内科学 | 834篇 |
皮肤病学 | 63篇 |
神经病学 | 165篇 |
特种医学 | 146篇 |
外科学 | 614篇 |
综合类 | 10篇 |
预防医学 | 52篇 |
眼科学 | 28篇 |
药学 | 124篇 |
中国医学 | 5篇 |
肿瘤学 | 443篇 |
出版年
2024年 | 3篇 |
2023年 | 41篇 |
2022年 | 68篇 |
2021年 | 133篇 |
2020年 | 90篇 |
2019年 | 103篇 |
2018年 | 116篇 |
2017年 | 87篇 |
2016年 | 120篇 |
2015年 | 107篇 |
2014年 | 149篇 |
2013年 | 134篇 |
2012年 | 237篇 |
2011年 | 222篇 |
2010年 | 124篇 |
2009年 | 92篇 |
2008年 | 197篇 |
2007年 | 200篇 |
2006年 | 154篇 |
2005年 | 182篇 |
2004年 | 173篇 |
2003年 | 148篇 |
2002年 | 129篇 |
2001年 | 18篇 |
2000年 | 21篇 |
1999年 | 25篇 |
1998年 | 22篇 |
1997年 | 22篇 |
1996年 | 16篇 |
1995年 | 13篇 |
1994年 | 11篇 |
1993年 | 15篇 |
1992年 | 8篇 |
1991年 | 7篇 |
1990年 | 1篇 |
1989年 | 4篇 |
1987年 | 5篇 |
1986年 | 5篇 |
1985年 | 2篇 |
1984年 | 1篇 |
1981年 | 1篇 |
1976年 | 2篇 |
1974年 | 2篇 |
1973年 | 1篇 |
1968年 | 2篇 |
1967年 | 1篇 |
1963年 | 1篇 |
1961年 | 1篇 |
排序方式: 共有3216条查询结果,搜索用时 125 毫秒
71.
72.
73.
Yohei Kawaguchi Masayuki Nakao Kenshiro Omura Naoya Iwamoto Hiroki Ozawa Yasuto Kondo Junji Ichinose Yosuke Matsuura Sakae Okumura Mingyon Mun 《Journal of thoracic disease》2020,12(12):7218
BackgroundIt is critical to have an accurate measurement of solid tumor size in order to predict the invasiveness of small lung adenocarcinomas. Some lesions cannot be measured accurately via High-resolution computed tomography (HRCT) due to their irregular shape and unclear borders. For this reason, we evaluated the relative efficacy of three-dimensional (3D) CT for predicting invasive adenocarcinoma.MethodsWe evaluated 195 patients with clinical stage IA adenocarcinomas, including 109 with lesions documented as invasive that were surgically resected at our institute during 2017. All lesions were categorized as either (I) lesions that were difficult to evaluate (i.e., hazy lesions; HL) or (II) more typical lesions (TL). The relationships between solid tumor size as determined by HRCT, solid tumor volume as determined by 3D CT and pathologic diagnosis were evaluated.ResultsFifty-seven patients (29%) were diagnosed with HL. We set the cut-off value for the solid volume at 225 mm3 as predictive for invasive adenocarcinoma. When evaluating all 195 patients as a group, the accuracy, sensitivity, and specificity based on the solid tumor volume were similar to those based on the solid tumor size. When we limit our analysis to the HL group, the specificity based on solid tumor volume (65.5%) was higher than that based on solid tumor size (44.8%) with a difference that approached statistical significance (P=0.070).Conclusions3D CT was equivalent to HRCT for predicting invasive adenocarcinoma and may be particularly useful for diagnosing lesions that are difficult to evaluate on HRCT. 相似文献
74.
75.
Masao Omata Shuhei Nishiguchi Yoshiyuki Ueno Hitoshi Mochizuki Namiki Izumi Fusao Ikeda Hidenori Toyoda Osamu Yokosuka Kazushige Nirei Takuya Genda Takeji Umemura Tetsuo Takehara Naoya Sakamoto Yoichi Nishigaki Kunio Nakane Nobuo Toda Tatsuya Ide Mikio Yanase Keisuke Hino Bing Gao Kimberly L. Garrison Hadas Dvory‐Sobol Akinobu Ishizaki Masa Omote Diana Brainard Steven Knox William T. Symonds John G. McHutchison Hiroshi Yatsuhashi Masashi Mizokami 《Journal of viral hepatitis》2014,21(11):762-768
Genotype 2 hepatitis C virus (HCV) accounts for up to 30% of chronic HCV infections in Japan. The standard of care for patients with genotype 2 HCV – peginterferon and ribavirin for 24 weeks – is poorly tolerated, especially among older patients and those with advanced liver disease. We conducted a phase 3, open‐label study to assess the efficacy and safety of an all‐oral combination of the NS5B polymerase inhibitor sofosbuvir and ribavirin in patients with chronic genotype 2 HCV infection in Japan. We enrolled 90 treatment‐naïve and 63 previously treated patients at 20 sites in Japan. All patients received sofosbuvir 400 mg plus ribavirin (weight‐based dosing) for 12 weeks. The primary endpoint was sustained virologic response at 12 weeks after therapy (SVR12). Of the 153 patients enrolled and treated, 60% had HCV genotype 2a, 11% had cirrhosis, and 22% were over the aged 65 or older. Overall, 148 patients (97%) achieved SVR12. Of the 90 treatment‐naïve patients, 88 (98%) achieved SVR12, and of the 63 previously treated patients, 60 (95%) achieved SVR12. The rate of SVR12 was 94% in patients with cirrhosis and in those aged 65 and older. No patients discontinued study treatment due to adverse events. The most common adverse events were nasopharyngitis, anaemia and headache. Twelve weeks of sofosbuvir and ribavirin resulted in high rates of SVR12 in treatment‐naïve and previously treated patients with chronic genotype 2 HCV infection. The treatment was safe and well tolerated by patients, including the elderly and those with cirrhosis. 相似文献
76.
Masatsugu Ohara Goki Suda Megumi Kimura Osamu Maehara Tomoe Shimazaki Taku Shigesawa Kazuharu Suzuki Akihisa Nakamura Naoki Kawagishi Masato Nakai Takuya Sho Mitsuteru Natsuizaka Kenichi Morikawa Koji Ogawa Tomoe Kobayashi Minoru Uebayashi Ryo Takagi Isao Yokota Tsuyoshi Shimamura Naoya Sakamoto 《Hepatology research》2020,50(6):715-725
77.
78.
Short‐ and long‐term results of lateral pancreaticojejunostomy for chronic pancreatitis: a retrospective Japanese single‐center study 下载免费PDF全文
79.
80.